Stereotaxis to Report Second Quarter Financial Results on August 9, 2022

Rhea-AI Summary

Stereotaxis (NYSE: STXS), a leader in surgical robotics for minimally invasive endovascular intervention, announced the release of its financial results for Q2 2022 on August 9, 2022, prior to market open. The company will host a conference call at 10 a.m. ET to discuss its financial performance and corporate developments. Stereotaxis aims to enhance patient care through advanced robotic systems, having treated over 100,000 patients globally.

Positive

• The company is set to discuss its Q2 2022 financial results, indicating transparency and engagement with investors.

Negative

• None.

ST. LOUIS, July 19, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2022 second quarter on Tuesday, August 9, 2022 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 10 a.m. ET that day to discuss the Company’s results and corporate developments.

What:	Stereotaxis second quarter 2022 financial results conference call
When:	Tuesday, August 9, 2022 at 10:00 a.m. ET (7:00 a.m. PT)
Dial In Number:	To access the live call, dial 888-394-8218 (US and Canada) or 1-856-344-9221 (International) and give the participant pass code 9211068.
Webcast:	To access the live and replay webcast, please visit the investor relations section of Stereotaxis’ website at http://ir.stereotaxis.com/
Call Replay:	A phone replay of the call will be available for one month beginning approximately two hours following the end of the call. To request access for a replay of the conference call, please click here.

About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 100,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com

Investor Contacts: David L. Fischel Chairman and Chief Executive Officer	Media Contact: Bethanne Schluter Director, Marketing & Communications
Kimberly Peery Chief Financial Officer
314-678-6100 Investors@Stereotaxis.com

FAQ

When will Stereotaxis release its Q2 2022 financial results?

Stereotaxis will release its Q2 2022 financial results on August 9, 2022, before the market opens.

What time is the Stereotaxis conference call for Q2 2022 results?

The conference call for Stereotaxis' Q2 2022 results will be held at 10 a.m. ET on August 9, 2022.

How can I access the Stereotaxis Q2 2022 earnings call?

To access the earnings call, dial 888-394-8218 (US) or 1-856-344-9221 (International) and use passcode 9211068.

What is Stereotaxis' mission in surgical robotics?

Stereotaxis focuses on developing robotic systems for minimally invasive procedures to enhance patient care and improve operational productivity.

How many patients has Stereotaxis treated with its technology?

Stereotaxis technology has been used to treat over 100,000 patients worldwide.